MA35190B1 - Anticorps anti-angptl3 et utilisations de ceux-ci - Google Patents

Anticorps anti-angptl3 et utilisations de ceux-ci

Info

Publication number
MA35190B1
MA35190B1 MA36579A MA36579A MA35190B1 MA 35190 B1 MA35190 B1 MA 35190B1 MA 36579 A MA36579 A MA 36579A MA 36579 A MA36579 A MA 36579A MA 35190 B1 MA35190 B1 MA 35190B1
Authority
MA
Morocco
Prior art keywords
diseases
disorders
hangptl3
human
human antibody
Prior art date
Application number
MA36579A
Other languages
English (en)
Inventor
Mark W Sleeman
Viktoria Gusarova
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35190(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA35190B1 publication Critical patent/MA35190B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un anticorps totalement humain ou un fragment de liaison d'antigène d'un anticorps humain qui se lie spécifiquement à et inhibe ou interfère avec au moins une activité de la protéine similaire à l'angiopoïétine humaine 3 (hangptl3). Les anticorps anti-hangptl3 humain sont utiles dans le traitement de maladies ou troubles associés à angptl3, tels que l'hyperlipidémie, l'hyperlipoprotéinémie et la dyslipidémie, comprenant l'hypertriglycéridémie, l'hypercholestérolémie, la chylomicronémie, etc. De plus, les anticorps anti-hangptl3 peuvent être administrés à un sujet nécessitant ceux-ci pour prévenir ou traiter des maladies ou troubles, pour lesquels un métabolisme anormal des lipides est un facteur de risque. De telles maladies ou de tels troubles comprennent les maladies cardiovasculaires, telles que l'athérosclérose et les maladies coronariennes ; la pancréatite aiguë ; la stéatose hépatique non alcoolique (nash) ; le diabète ; l'obésité ; et similaire.
MA36579A 2011-06-17 2013-12-17 Anticorps anti-angptl3 et utilisations de ceux-ci MA35190B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498518P 2011-06-17 2011-06-17
US201161578309P 2011-12-21 2011-12-21
PCT/US2012/042338 WO2012174178A1 (fr) 2011-06-17 2012-06-14 Anticorps anti-angptl3 et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
MA35190B1 true MA35190B1 (fr) 2014-06-02

Family

ID=46298728

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36579A MA35190B1 (fr) 2011-06-17 2013-12-17 Anticorps anti-angptl3 et utilisations de ceux-ci

Country Status (46)

Country Link
US (7) US9018356B2 (fr)
EP (2) EP2721065B1 (fr)
JP (2) JP6400471B2 (fr)
KR (1) KR102031007B1 (fr)
CN (1) CN103732624B (fr)
AR (1) AR087329A1 (fr)
AU (1) AU2012271663B2 (fr)
CA (1) CA2838867C (fr)
CL (1) CL2013003552A1 (fr)
CO (1) CO6821892A2 (fr)
CR (1) CR20130621A (fr)
CY (2) CY1120996T1 (fr)
DK (1) DK2721065T3 (fr)
DO (1) DOP2013000299A (fr)
EC (1) ECSP13013085A (fr)
ES (1) ES2699499T3 (fr)
FI (1) FIC20210028I1 (fr)
FR (1) FR21C1061I2 (fr)
GT (1) GT201300306A (fr)
HR (1) HRP20182098T1 (fr)
HU (1) HUS2100034I1 (fr)
IL (2) IL229612B (fr)
JO (1) JO3412B1 (fr)
LT (2) LT2721065T (fr)
LU (1) LUC00231I2 (fr)
MA (1) MA35190B1 (fr)
MX (2) MX337644B (fr)
MY (1) MY160516A (fr)
NI (1) NI201300136A (fr)
NL (1) NL301122I2 (fr)
NO (2) NO2021037I1 (fr)
PE (1) PE20141166A1 (fr)
PH (1) PH12013502570B1 (fr)
PL (1) PL2721065T3 (fr)
PT (1) PT2721065T (fr)
RS (1) RS58310B1 (fr)
RU (1) RU2620064C2 (fr)
SG (1) SG195165A1 (fr)
SI (1) SI2721065T1 (fr)
SM (1) SMT201800658T1 (fr)
TR (1) TR201816591T4 (fr)
TW (3) TW201920261A (fr)
UA (1) UA114891C2 (fr)
UY (2) UY34137A (fr)
WO (1) WO2012174178A1 (fr)
ZA (1) ZA201308879B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3412B1 (ar) * 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2017011929A1 (fr) * 2015-07-17 2017-01-26 北京大学第一医院 Utilisation d'une substance pour détecter la teneur en protéine de type angiopoïétine 2 dans le sérum pour la préparation de produits destinés à détecter l'inflammation et le degré de fibrose du foie
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
ES2951262T3 (es) * 2016-02-17 2023-10-19 Regeneron Pharma Métodos para tratar o prevenir la aterosclerosis mediante la administración de un inhibidor de ANGPTL3
KR102456731B1 (ko) * 2016-03-03 2022-10-24 리제너론 파아마슈티컬스, 인크. Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
LT3439689T (lt) * 2016-04-08 2021-11-10 Regeneron Pharmaceuticals, Inc. Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi
CA3021884A1 (fr) * 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methodes de traitement de patients presentant une hypercholesterolemie familiale
WO2018039499A1 (fr) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Modification de protéines de cellules hôtes
EA201991203A1 (ru) 2016-11-17 2019-10-31 Способы лечения ожирения антителами к angptl8
CN114075269A (zh) 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
WO2019126194A1 (fr) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Dosage d'angptl8 et ses utilisations
CN111479618B (zh) 2017-12-22 2022-08-02 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
KR20200115485A (ko) 2018-01-31 2020-10-07 리제너론 파마슈티칼스 인코포레이티드 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
US12460270B2 (en) 2018-02-28 2025-11-04 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
BR112020015291B1 (pt) 2018-03-19 2023-09-26 Regeneron Pharmaceuticals, Inc Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
KR20210053816A (ko) 2018-08-30 2021-05-12 리제너론 파마슈티칼스 인코포레이티드 단백질 복합체를 특성화하기 위한 방법
WO2020109978A1 (fr) * 2018-11-26 2020-06-04 Novartis Ag Polypeptides de fusion de lpl-gpihbp1
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
IL284471B2 (en) 2019-01-16 2025-01-01 Regeneron Pharma Methods for identifying free thiols in proteins
US20220144961A1 (en) * 2019-03-11 2022-05-12 Xyence Therapeutics, Inc. Cd27-binding antibodies and uses thereof
EP3969908A1 (fr) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Dosages améliorés de liaison de ligands compétitifs
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
MX2022000094A (es) * 2019-07-04 2022-04-27 Cadila Healthcare Ltd Vacuna a base de angptl3 para el tratamiento de enfermedad hepática.
EP4653865A3 (fr) 2019-09-24 2026-02-18 Regeneron Pharmaceuticals, Inc. Systèmes et procédés d'utilisation et de régénération de chromatographie
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
MX2022006236A (es) 2019-11-25 2022-06-22 Regeneron Pharma Formulaciones de liberacion sostenida con emulsiones no acuosas.
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
KR102544013B1 (ko) 2020-01-21 2023-06-19 리제너론 파마슈티칼스 인코포레이티드 당질화된 단백질의 전기영동을 위한 탈당질화 방법
EP4095157A4 (fr) * 2020-01-22 2024-04-10 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticorps anti-angptl3 et son utilisation
CA3192999A1 (fr) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Strategies d'alimentation d'asparagine pour ameliorer la performance de culture cellulaire et attenuer des variants de sequence d'asparagine
EP4251128A1 (fr) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Formulations à libération prolongée à l'aide d'une émulsification par membrane non aqueuse
WO2022133135A1 (fr) 2020-12-17 2022-06-23 Regeneron Pharmaceuticals, Inc. Fabrication de microgels encapsulant des protéines
CN116761880A (zh) 2021-01-20 2023-09-15 瑞泽恩制药公司 改进细胞培养物中的蛋白质滴度的方法
CA3207883A1 (fr) 2021-03-03 2022-09-09 Xiaobin Xu Systemes et procedes de quantification et de modification de la viscosite de proteines
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
US20220309215A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
US20240092884A1 (en) * 2021-03-30 2024-03-21 Children's Hospital Of Fudan University Anti-angptl3 antibody or antigen-binding fragment thereof, and preparation method and use thereof
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EP4375298A4 (fr) * 2021-07-21 2025-02-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Composition pharmaceutique d'anticorps anti-angptl3 ou de fragment de liaison à l'antigène de celui-ci et son application
WO2023039457A1 (fr) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. Procédé à haut rendement et fondé sur la spectrométrie de masse pour quantifier des anticorps et d'autres protéines contenant fc
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
CN118076894A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH建模和控制的系统及方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
KR20240097864A (ko) 2021-10-26 2024-06-27 리제너론 파마슈티칼스 인코포레이티드 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
CN116284377A (zh) * 2021-12-21 2023-06-23 复旦大学 抗人血管生成素3纳米抗体及其应用
US20230193271A1 (en) * 2021-12-22 2023-06-22 Regeneron Pharmaceuticals, Inc. Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors
CA3245647A1 (fr) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Procédés et systèmes permettant d'analyser des variants polypeptidiques
WO2023213779A1 (fr) * 2022-05-02 2023-11-09 Novo Nordisk A/S Nouveaux anticorps anti-angptl3 appropriés pour des compositions à concentration élevée et administration sous-cutanée
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白
CN116143919B (zh) * 2022-11-01 2025-06-13 中国药科大学 全人源抗人nt-angptl3抗体、其抗原结合片段及其应用
WO2024130165A1 (fr) * 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Inhibiteurs de l'angptl3 pour la réduction des triglycérides dans le syndrome de chylomicronémie multifactorielle
TW202435942A (zh) 2022-12-16 2024-09-16 美商里珍納龍藥品有限公司 評估層析管柱完整性的方法及系統
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445126A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 基於質譜法之體內共表現抗體之表徵
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
WO2024178213A2 (fr) 2023-02-22 2024-08-29 Regeneron Pharmaceuticals, Inc. Paramètres d'adéquation de système et vieillissement de colonne
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (fr) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Procédés et systèmes pour développer des protocoles de chromatographie
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (fr) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Plateforme d'analyse par spectrométrie de masse à détection de charge d'aavs
WO2025175164A1 (fr) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Procédés de production de substances médicamenteuses formulées concentrées comprenant des protéines, et substance médicamenteuse formulée concentrée fabriquée par les procédés
WO2025194043A1 (fr) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate et polyoxyéthylène sorbitane utilisés en tant qu'excipients pour formulations de protéines stables
WO2025259840A1 (fr) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Procédés et systèmes de chromatographie mise à l'échelle
WO2026025028A1 (fr) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Procédés de fabrication de formulations protéiques à concentration ultra-élevée par lyophilisation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
AU2001259099B2 (en) 2001-02-22 2005-12-22 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
EP1451578B1 (fr) * 2001-11-16 2013-08-21 Genentech, Inc. Utilisation d' antagonistes de angptl3 pour le traitement des maladies inflammatoires du foie
EP2322203A3 (fr) 2002-10-29 2011-07-27 Genentech, Inc. Les compositions et les methodes pour le traitement de maladies liees immunisees
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP2008532516A (ja) 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
JP5489465B2 (ja) 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
WO2008054606A2 (fr) * 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. Anticorps humains à haute affinité vis-à-vis du récepteur il-4 humain
CN101855241B (zh) * 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2216016A1 (fr) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
PL2453921T3 (pl) 2009-07-14 2015-11-30 Scripps Research Inst Różnicowanie mezenchymalnych komórek macierzystych
EP2521556B1 (fr) 2010-01-08 2018-05-30 Ionis Pharmaceuticals, Inc. Modulation de l'expression de l'analogue de l'angiopoïétine 3
JO3412B1 (ar) * 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CN103890000B (zh) * 2011-06-21 2017-09-01 阿尔尼拉姆医药品有限公司 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
CN105814204B (zh) 2013-12-24 2020-04-28 Ionis制药公司 促血管生成素样3表达的调节
ES2844593T3 (es) 2014-05-01 2021-07-22 Ionis Pharmaceuticals Inc Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
ES2951262T3 (es) 2016-02-17 2023-10-19 Regeneron Pharma Métodos para tratar o prevenir la aterosclerosis mediante la administración de un inhibidor de ANGPTL3
KR102456731B1 (ko) 2016-03-03 2022-10-24 리제너론 파아마슈티컬스, 인크. Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
LT3439689T (lt) 2016-04-08 2021-11-10 Regeneron Pharmaceuticals, Inc. Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi
CA3021884A1 (fr) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methodes de traitement de patients presentant une hypercholesterolemie familiale
US12559551B2 (en) * 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies

Also Published As

Publication number Publication date
PL2721065T3 (pl) 2019-02-28
IL259436A (en) 2018-07-31
CL2013003552A1 (es) 2014-07-25
LTPA2021009I1 (fr) 2021-09-27
US9951127B2 (en) 2018-04-24
PH12013502570A1 (en) 2014-01-27
LUC00231I2 (fr) 2025-02-03
MY160516A (en) 2017-03-15
US20220153825A1 (en) 2022-05-19
JO3412B1 (ar) 2019-10-20
US10358487B2 (en) 2019-07-23
US20250136675A1 (en) 2025-05-01
DOP2013000299A (es) 2014-04-15
EP2721065B1 (fr) 2018-09-12
JP2014523739A (ja) 2014-09-18
RU2013155906A (ru) 2015-07-27
LT2721065T (lt) 2018-12-10
SG195165A1 (en) 2013-12-30
US20190315851A1 (en) 2019-10-17
HUS2100034I1 (hu) 2021-10-28
CR20130621A (es) 2014-02-12
DK2721065T3 (en) 2018-12-03
GT201300306A (es) 2015-03-09
TW201920261A (zh) 2019-06-01
HRP20182098T1 (hr) 2019-02-08
SMT201800658T1 (it) 2019-01-11
PE20141166A1 (es) 2014-09-16
MX337644B (es) 2016-03-14
AU2012271663B2 (en) 2017-04-20
NO2021037I1 (no) 2021-09-15
KR102031007B1 (ko) 2019-11-08
TW201815822A (zh) 2018-05-01
LTC2721065I2 (fr) 2022-10-25
UA114891C2 (uk) 2017-08-28
CA2838867A1 (fr) 2012-12-20
NL301122I2 (nl) 2021-12-30
AR087329A1 (es) 2014-03-19
CY2021036I1 (el) 2022-03-24
MX2013014345A (es) 2014-01-31
US20150197564A1 (en) 2015-07-16
JP2018166516A (ja) 2018-11-01
FR21C1061I2 (fr) 2022-11-18
UY34137A (es) 2013-01-03
CN103732624B (zh) 2016-08-17
NO2025028I1 (no) 2025-06-13
NL301122I1 (fr) 2021-09-01
NZ619092A (en) 2016-03-31
ZA201308879B (en) 2014-07-30
EP3418301A1 (fr) 2018-12-26
SI2721065T1 (sl) 2018-12-31
RS58310B1 (sr) 2019-03-29
US20190092845A1 (en) 2019-03-28
JP6400471B2 (ja) 2018-10-03
FR21C1061I1 (fr) 2022-01-21
KR20140037218A (ko) 2014-03-26
ES2699499T3 (es) 2019-02-11
MX361859B (es) 2018-12-18
CO6821892A2 (es) 2013-12-31
TW201313738A (zh) 2013-04-01
UY39340A (es) 2021-08-31
TWI644922B (zh) 2018-12-21
IL229612A0 (en) 2014-01-30
CA2838867C (fr) 2020-07-14
WO2012174178A1 (fr) 2012-12-20
IL229612B (en) 2019-06-30
PT2721065T (pt) 2018-12-06
ECSP13013085A (es) 2014-01-31
US20130171149A1 (en) 2013-07-04
RU2620064C2 (ru) 2017-05-22
PH12013502570B1 (en) 2019-01-16
US9018356B2 (en) 2015-04-28
CN103732624A (zh) 2014-04-16
NI201300136A (es) 2014-05-15
FIC20210028I1 (fi) 2021-09-09
AU2012271663A1 (en) 2014-01-16
CY1120996T1 (el) 2019-12-11
TR201816591T4 (tr) 2018-11-21
EP2721065A1 (fr) 2014-04-23
US20220403016A1 (en) 2022-12-22
CY2021036I2 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
MA35190B1 (fr) Anticorps anti-angptl3 et utilisations de ceux-ci
MA44764A (fr) Méthodes de traitement de patients présentant une hypercholestérolémie familiale
Kereiakes et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study
BR112012017765A2 (pt) anticorpos humanos para proteína semelhante à angiopoietina humana-4
Bays et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia
Braamskamp et al. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
MA29931B1 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
Elalfy et al. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study
Santos et al. Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA38144A1 (fr) Compositions et procédés pour le traitement de protéinopathies
MA33724B1 (fr) Anticorps neutralisants anti-ngf humain en tant qu'inhibiteurs selectifs de la voie du ngf
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA33387B1 (fr) Polypeptides et procede de traitement
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
Zieve et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients≥ 65 years of age (from the ZETia in the ELDerly [ZETELD] study)
MA31437B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA34670B1 (fr) Inhibiteurs de l'apoptose et leurs utilisations
MA30720B1 (fr) Analogues de 2-phenoxypyrimidinone
Julius et al. Effects of lipoprotein apheresis on PCSK9 levels
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
MA29723B1 (fr) Composes
MA37670B1 (fr) Anticorps anti-transglutaminase 2